A small Phase 1 trial run by Life Biosciences tested a novel partial cell‑reprogramming therapy to restore function to retinal ganglion cells in people with glaucoma. Three patients received injections of engineered transcription factors into the eye’s vitreous, activated for eight weeks by doxycycline, and the treatment was reported as safe with only injection‑related side effects. Two of the participants showed measurable improvement in visual field testing eight weeks after treatment, prompting plans to test a threefold higher dose. The approach targets retinal ganglion cells that lose their long connections to the optic nerve under pressure from poor fluid drainage; the goal is to restore those cells’ ability to transmit visual signals rather than to replace them.
The therapy builds on David Sinclair’s epigenetic‑reprogramming framework and on Yuancheng Lu’s mouse work that regenerated ganglion cell connections, using three of the four Yamanaka factors to avoid the cancer risk associated with full reprogramming. The three factors were sized to fit delivery tools and are made active only in the presence of doxycycline, providing an on/off safety control. Investigators hope the dose escalation and further trials could extend to other eye conditions such as NAION and eventually to rejuvenating cells in other organs if safety and efficacy hold up.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.